HALO vs TROW · P/E 15, rev $857.7M vs P/E 12, rev $3.76B
Halozyme Therapeutics Inc (HALO) versus T. Rowe Price Group Inc (TROW) — a side-by-side from cached financials, not a winner call.
Halozyme Therapeutics Inc (HALO) is a biotechnology company listed on US.
T. Rowe Price Group Inc (TROW) is a asset management company listed on NASDAQ.
Latest reported HALO revenue for 2026-06-30 was $857.7M. Net income was $380.0M. HALO currently screens at market cap $7.10B and trailing P/E 15.3.
Latest reported TROW revenue for 2026-06-30 was $3.76B. Net income was $1.13B. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
HALO currently screens at market cap $7.10B and trailing P/E 15.3. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
Not investment advice. Open the HALO and TROW stock pages for the full models.
Not investment advice.